Trial Profile
Phase III study on dose response of SMP-508 monotherapy in patients with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2016
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 31 May 2016 New trial record